Combination Therapy for Crohn's: Biologic + Immunomodulator

Combination therapy for Crohn's disease - using a biologic alongside an immunomodulator - is one of the most studied strategies for pushing moderate-to-severe disease toward deep, lasting remission. But the story is more nuanced than "two drugs are better than one." Landmark trials like SONIC and SPARE have shaped how gastroenterologists think about starting, maintaining, and eventually stepping down this approach, and the 2025 AGA guideline now treats combination therapy differently depending on which biologic you are taking.

If you are beginning a biologic, already on combination therapy, or wondering whether you really still need both medications, this guide walks through the evidence so you can have a more informed conversation with your care team.

Key Takeaways

• In the SONIC trial, 56.8% of patients on infliximab plus azathioprine achieved steroid-free remission at week 26 - compared with 44.4% on infliximab alone and 30.0% on azathioprine alone (1)
• Combination therapy works partly by reducing antibodies your body makes against the biologic, which helps maintain higher drug levels and better disease control
• The SPARE trial found that patients who dropped the immunomodulator while keeping infliximab had similar relapse rates to those who continued both drugs at two years (4)
• Evidence is strongest for infliximab-based combinations; the DIAMOND trial showed that adding azathioprine to adalimumab did not improve the primary remission endpoint (3)
• The 2025 AGA guideline addresses combination therapy differently across biologic classes, reflecting the varying strength of evidence (6)

What Is Combination Therapy in Crohn's Disease?

Combination therapy means taking a biologic medication together with an immunomodulator to treat Crohn's disease. The biologic is typically an anti-TNF agent such as infliximab, while the immunomodulator is usually azathioprine, 6-mercaptopurine, or methotrexate. The two drugs work through different pathways, and combining them aims to achieve two things: better disease control and a lower chance that your immune system will neutralize the biologic.

Which Biologics and Immunomodulators Are Used Together

The pairing with the most evidence behind it is infliximab plus azathioprine or 6-mercaptopurine. Adalimumab (Humira) has also been studied in combination, though with less clear-cut results. For newer biologic classes - including ustekinumab, vedolizumab, and risankizumab - data on combination therapy are more limited, and the benefit of adding an immunomodulator appears smaller or is still being studied.

How Combination Therapy Differs From Monotherapy and Top-Down Therapy

It is easy to confuse combination therapy with top-down therapy, but they are not the same thing. Top-down refers to starting a biologic early in the disease course rather than waiting for older medications to fail - it is about timing. Combination therapy is about using two drugs at the same time regardless of when you start. You can receive top-down treatment as monotherapy (a biologic alone, started early), or you can receive combination therapy at any stage of disease. In practice, the two strategies often overlap, but the distinction matters when reading research or discussing options with your doctor.

The SONIC Trial: Landmark Evidence for Combination Therapy

The Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease (SONIC) is the single most important trial in the combination therapy story. Published in the New England Journal of Medicine in 2010, it set the benchmark that gastroenterologists still reference today (1).

What the Trial Tested and Who Was Enrolled

SONIC enrolled adults with moderate-to-severe Crohn's disease who had never received a biologic or an immunosuppressant. Patients were randomly assigned to one of three groups: infliximab alone, azathioprine alone, or both together (1). By focusing on treatment-naive patients, the trial gave the clearest possible picture of what each strategy could achieve from the start.

The Steroid-Free Remission and Mucosal Healing Results

At week 26, the results were striking. Steroid-free clinical remission was reached by 56.8% of patients on combination therapy, 44.4% on infliximab alone, and 30.0% on azathioprine alone (1). Mucosal healing - visible improvement of the intestinal lining on endoscopy - was also significantly more common in the combination group than in either monotherapy group (1). These numbers established combination therapy as the most effective first-line approach for anti-TNF treatment in many patients with moderate-to-severe Crohn's.

Why Combination Therapy Works: Drug Levels and Antibodies

Understanding why two drugs can outperform one helps make sense of your treatment plan. The explanation goes beyond simply attacking inflammation from two directions.

How Immunomodulators Reduce Anti-Drug Antibodies

Biologics are large proteins, and your immune system can sometimes recognize them as foreign and produce antibodies against them - called anti-drug antibodies. When this happens, the biologic gets cleared from your bloodstream faster, drug levels drop, and the medication stops working as well. Adding an immunomodulator damps down this antibody response, helping the biologic stay at effective levels in your body for longer. This effect is especially well-documented for infliximab, which is more immunogenic (more likely to trigger antibody formation) than some newer biologics.

The Role of Therapeutic Drug Monitoring

Therapeutic drug monitoring (TDM) measures the actual levels of biologic in your blood and checks for anti-drug antibodies. Higher biologic drug levels consistently correlate with better clinical outcomes, and combination therapy tends to raise these levels. TDM is also one of the tools clinicians use to decide whether you still need both drugs - if your drug levels are consistently high and antibodies are undetectable, it may signal that the immunomodulator has done its job and could potentially be withdrawn.

Risks to Weigh: Infections, Lymphoma, and Side Effects

No honest discussion of combination therapy can skip the trade-offs. Using two immune-suppressing medications together increases certain risks that you and your doctor need to weigh against the benefits.

Infection Risk With Dual Immune Suppression

Combination therapy raises the risk of serious infections compared with either drug alone. This includes bacterial infections, viral reactivations, and, in rare cases, opportunistic infections. Your gastroenterologist will likely screen for tuberculosis and hepatitis B before starting, and you should stay current on vaccinations - ideally before beginning immunosuppressive treatment.

Cancer Signals With Thiopurines

Long-term use of thiopurines (azathioprine and 6-mercaptopurine) has been associated with an increased risk of lymphoma. In young men, the risk of hepatosplenic T-cell lymphoma - an extremely rare but often fatal cancer - has been specifically linked to thiopurine exposure, particularly when combined with an anti-TNF biologic. The absolute risk remains small, but it is real and should be part of the shared decision-making process. Long-term thiopurine use also increases the risk of nonmelanoma skin cancers, so regular dermatologic screening is advisable.

The DIAMOND Trial: A Different Result for Adalimumab

Not every biologic-immunomodulator combination shows the same benefit. The DIAMOND trial, conducted in Japan, tested adalimumab plus azathioprine against adalimumab alone. For the primary endpoint of steroid-free remission, azathioprine did not add a statistically significant benefit, and side effects from azathioprine prompted many patients to discontinue it (3). This result does not mean combination therapy never works with adalimumab, but it does mean the case is less clear-cut than it is for infliximab.

When to De-escalate: The SPARE Trial

One of the most common questions patients on combination therapy ask is: "Do I have to stay on both drugs forever?" The SPARE trial, published in The Lancet Gastroenterology and Hepatology in 2023, directly addressed this (4).

What SPARE Asked About Withdrawing One Drug

SPARE enrolled patients with Crohn's disease who were in sustained steroid-free remission on infliximab combined with an immunosuppressant. It randomized them into three groups: continue both drugs, stop the immunosuppressant but keep infliximab, or stop infliximab but keep the immunosuppressant (4). This design let researchers directly compare which drug is safer to remove.

How to Think About the Tradeoff of Relapse Risk

At two years, continuing both drugs and stopping the immunosuppressant produced similar relapse rates - both significantly lower than the group that stopped infliximab (4). Patients who stopped infliximab relapsed more often, although many were able to recapture remission when infliximab was restarted (4). The practical implication is reassuring for many patients: if you have been in sustained remission on combination therapy, carefully dropping the immunomodulator while keeping your biologic may be a reasonable option - reducing side-effect exposure without dramatically raising your relapse risk.

Combination Therapy in the 2025 AGA Guideline and Newer Biologics

The landscape continues to evolve. The 2025 AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease now provides updated, drug-class-specific recommendations on when combination therapy is and is not preferred (6).

What the AGA Recommends Today

Combination therapy remains most strongly supported for infliximab, reflecting the robust evidence from SONIC and other trials. For other biologics - ustekinumab, risankizumab, vedolizumab - the guideline's stance is more nuanced, reflecting weaker or mixed data on whether adding an immunomodulator meaningfully improves outcomes. A 2021 network meta-analysis in The Lancet Gastroenterology and Hepatology, which compared the efficacy and safety of biologic therapies for moderate-to-severe Crohn's, also informs current guidance and helps place combination strategies in context alongside newer agents (2).

Combination Approaches With Newer Drug Classes

Some specialist centers are pushing the boundaries further. A 2025 case series in Alimentary Pharmacology and Therapeutics described using upadacitinib - a JAK inhibitor - together with a biologic (infliximab, risankizumab, ustekinumab, or vedolizumab) for patients with refractory Crohn's disease (5). This is an off-guideline strategy reserved for patients who have not responded to standard options, and it highlights both the unmet need in refractory disease and the caution required when combining newer agents. This approach should only be considered at experienced centers with close monitoring.

Talking With Your Gastroenterologist

The decision around combination therapy is deeply personal and depends on your individual disease history, risk factors, and treatment goals. Here are concrete ways to make that conversation more productive.

Questions to Bring to Your Next Appointment

• Which biologic are you recommending, and is combination therapy being considered for me?
• Have I been tested for TPMT and NUDT15 (enzyme tests that predict thiopurine side effects)?
• How long do you plan for me to stay on combination therapy, and when will we revisit de-escalation?
• Will therapeutic drug monitoring be part of my care so we can track drug levels and antibodies?
• Given my age, sex, and medical history, what are the specific risks I should understand?

How Your History Changes the Decision

Your prior experience with thiopurines or methotrexate matters - if you have already had side effects or intolerance, your doctor may lean toward biologic monotherapy or a different immunomodulator. A personal or family history of cancer, particularly lymphoma, shifts the risk calculus. Previous infections, current hepatitis B status, and vaccination history all factor in. And if you have been on combination therapy for years and are in deep remission, the SPARE trial data may support a conversation about stepping down. The right answer is different for every patient - what matters is that the conversation happens.

Frequently Asked Questions

Is combination therapy always better than a biologic alone for Crohn's?

Not always. The strongest evidence favoring combination therapy is for infliximab, where the SONIC trial showed significantly higher remission rates (1). For adalimumab, the DIAMOND trial found that adding azathioprine did not clearly improve the primary endpoint (3). For newer biologics like ustekinumab and vedolizumab, the data are mixed. Your gastroenterologist will weigh the evidence for your specific biologic.

How long do I need to stay on combination therapy?

There is no single answer. Many gastroenterologists start with at least 6 to 12 months of combination therapy to establish remission and suppress anti-drug antibodies, then reassess. The SPARE trial showed that patients in sustained remission could often stop the immunomodulator while continuing infliximab without a major increase in relapse risk (4).

What are the most serious risks of combination therapy?

The main concerns are an increased risk of serious infections from dual immune suppression and a small but real risk of lymphoma associated with long-term thiopurine use. Young men face a particularly rare risk of hepatosplenic T-cell lymphoma. Nonmelanoma skin cancer risk is also elevated. These risks are part of why de-escalation is discussed once remission is established.

Can I use methotrexate instead of azathioprine in combination therapy?

Yes, methotrexate is an alternative immunomodulator that some gastroenterologists prefer, particularly for patients who do not tolerate thiopurines. It carries a different side-effect profile - including liver and lung concerns - but does not carry the same lymphoma signal as thiopurines. The choice between azathioprine and methotrexate depends on your individual history and your doctor's assessment.

What is TPMT testing and why does it matter for combination therapy?

TPMT (thiopurine methyltransferase) is an enzyme that metabolizes thiopurine drugs like azathioprine and 6-mercaptopurine. A blood test can determine whether you have normal, intermediate, or low TPMT activity. Patients with low or absent TPMT activity are at high risk of severe bone marrow suppression if given standard thiopurine doses. NUDT15 testing serves a similar purpose. Both tests are typically ordered before starting a thiopurine.

Does combination therapy work for newer biologics like ustekinumab or vedolizumab?

The evidence is less clear than it is for infliximab. Some studies suggest that adding an immunomodulator to ustekinumab or vedolizumab may help reduce anti-drug antibody formation, but the clinical benefit in terms of remission rates has not been as convincingly demonstrated. The 2025 AGA guideline reflects this uncertainty (6). Discuss the specific evidence for your biologic with your gastroenterologist.

Should I ask my doctor about de-escalation if I'm in remission?

Yes. If you have been in stable, steroid-free remission on combination therapy for a sustained period, it is reasonable to ask whether de-escalation - typically stopping the immunomodulator while continuing the biologic - might be appropriate for you. The SPARE trial provides evidence supporting this approach in selected patients (4). Therapeutic drug monitoring can help guide the decision by confirming that your biologic levels remain adequate.

References

1. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine, 2010. Read study
2. Singh S, Murad MH, Fumery M, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. The Lancet Gastroenterology and Hepatology, 2021. Read study
3. Hisamatsu T, Matsumoto T, Watanabe K, et al. Concerns and side effects of azathioprine during adalimumab induction and maintenance therapy for Japanese patients with Crohn's disease: a subanalysis of a prospective randomised clinical trial (DIAMOND). Journal of Crohn's and Colitis, 2019. Read study
4. Louis E, Resche-Rigon M, Laharie D, et al. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE). The Lancet Gastroenterology and Hepatology, 2023. Read study
5. Dalal RS, Clarke LM, Cabral HJ, et al. Combination therapy of upadacitinib with infliximab, risankizumab, ustekinumab or vedolizumab for refractory Crohn's disease: a descriptive case series. Alimentary Pharmacology and Therapeutics, 2025. Read study
6. Scott FI, Ananthakrishnan AN, Click B, et al. AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease. Gastroenterology, 2025. Read study